's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

»'s Bulletin Board » OTCBB Reporting Stocks » ..Italian Laboratory Expands ProtoKinetix’ Market for AAGP™ » Post A Reply

Post A Reply
Login Name:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    

HTML is not enabled.
UBB Code™ is enabled.


Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?

Disable Graemlins in this post.


T O P I C     R E V I E W
jackbequick  - posted
..Italian Laboratory Expands ProtoKinetix’ Market for AAGP™

..Vancouver, British Columbia, December 7th, 2011

...ProtoKinetix (OTCBB: PKTX) ( is pleased to announce results from Areta International laboratory in Italy.

..These results show dramatic increases in the production of monoclonal antibodies when AAGP™ is incorporated into the production cycle. Monoclonal antibodies are one of the fastest growing sectors of the pharmaceutical industry. This market is presently over $50-billion USD per year and growing rapidly. As a therapeutic, monoclonal antibodies do not cause the same side-effects of chemotherapy and radiation treatment.

..Since the Company continues to focus on the anti-inflammation applications of AAGP™, they intend to partner the monoclonal antibody development to pharmaceutical laboratories.

..Monoclonal antibodies have proven themselves to be highly effective therapies and diagnostics, in a growing list of diseases. Access to this class of drug is extremely restricted, due to the prohibitive cost.

..In order for monoclonal antibodies to be universally available, the cost has to be aggressively reduced.
Initial results from these tests demonstrate a 300% to 500% increase in monoclonal antibody production in the presence of AAGP™.

..This significant increase in yield, will result in major cost reductions for the treatment of cardio vascular disease, auto-immune disorders, leukemia, transplant rejection, cancer as well as numerous diagnostics.

Contact Us | Message Board Home

© 1997 - 2018 All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2